These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17911587)

  • 1. Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL.
    Luketic L; Delanghe J; Sobol PT; Yang P; Frotten E; Mossman KL; Gauldie J; Bramson J; Wan Y
    J Immunol; 2007 Oct; 179(8):5024-32. PubMed ID: 17911587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.
    Nelson D; Bundell C; Robinson B
    J Immunol; 2000 Dec; 165(11):6123-32. PubMed ID: 11086045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.
    Warren TL; Bhatia SK; Acosta AM; Dahle CE; Ratliff TL; Krieg AM; Weiner GJ
    J Immunol; 2000 Dec; 165(11):6244-51. PubMed ID: 11086059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells.
    Rubinstein MP; Kadima AN; Salem ML; Nguyen CL; Gillanders WE; Cole DJ
    J Immunol; 2002 Nov; 169(9):4928-35. PubMed ID: 12391205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential.
    Kelleher M; Beverley PC
    J Immunol; 2001 Dec; 167(11):6247-55. PubMed ID: 11714787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination.
    Matsuyoshi H; Senju S; Hirata S; Yoshitake Y; Uemura Y; Nishimura Y
    J Immunol; 2004 Jan; 172(2):776-86. PubMed ID: 14707047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
    Krishnan L; Sad S; Patel GB; Sprott GD
    J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E; Celis E
    J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
    Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
    J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
    Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
    J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells.
    del Rio ML; Rodriguez-Barbosa JI; Kremmer E; Förster R
    J Immunol; 2007 Jun; 178(11):6861-6. PubMed ID: 17513734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo.
    Kleindienst P; Brocker T
    J Immunol; 2003 Mar; 170(6):2817-23. PubMed ID: 12626531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
    Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
    Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
    Porgador A; Gilboa E
    J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+ T cells can protect APC from CTL-mediated elimination.
    Mueller SN; Jones CM; Stock AT; Suter M; Heath WR; Carbone FR
    J Immunol; 2006 Jun; 176(12):7379-84. PubMed ID: 16751382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function.
    Dumortier H; van Mierlo GJ; Egan D; van Ewijk W; Toes RE; Offringa R; Melief CJ
    J Immunol; 2005 Jul; 175(2):855-63. PubMed ID: 16002683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.
    Nelson DJ; Mukherjee S; Bundell C; Fisher S; van Hagen D; Robinson B
    J Immunol; 2001 May; 166(9):5557-66. PubMed ID: 11313395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.